At a glance
- Originator Novartis
- Class Antihyperlipidaemics
- Mechanism of Action Sterol O-acyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 13 Feb 1995 No-Development-Reported for Hypercholesterolaemia in Switzerland (Unknown route)